Researchers find sarcoma tumor immune response with combination therapy

A team of 18 researchers at Moffitt Cancer Center in Tampa, Fla., have found that treating high-risk, soft tissue sarcoma patients with a combination of implanted dendritic cells (immune system cells) and fractionated external beam radiation (EBRT) provided more than 50 percent of their trial patients with tumor-specific immune responses lasting from 11 to 42 weeks.

Their study was published in a recent issue of the International Journal of * Biology * Physics (Vol. 82, No. 2), the journal of the American Society for Radiation Oncology (ASTRO).

"Sarcomas are relatively rare forms of cancer with about 10,000 new cases in the U.S. annually," said study co-author Dmitry Gabrilovich, M.D., Ph.D., senior member of the Moffitt Department of Immunology.

The authors note that because 50 percent of patients with large, high-grade soft tissue sarcomas develop distant metastasis, new, effective treatments are needed.

"Unfortunately, for large, high-grade tumors is frequently systematically ineffective, making this a very deadly problem," Gabrilovich said.

According to the researchers, administration of has been found to be a promising method for producing an immune response because dendritic cells process antigen material and present it to other . Dendritic cells act as immune system messengers.

"Many studies have shown that preoperative radiotherapy and surgery is effective in treating many soft tissue sarcomas with high-risk features," said Gabrilovich. "We designed our study to investigate the effect of combining the administration of dendritic cells and EBRT for patients with soft tissue, high-risk sarcomas."

The researchers hypothesized that if dendritic cell implants were combined with EBRT (the most common kind of radiotherapy treatment that not only can kill but release tumor antigens) the combination therapy might be complimentary when the dendritic cells helped process tumor antigens released by the EBRT treatment.

"The combination treatment resulted in dramatic increases in immune T cells in the tumors," explained Gabrilovich. "The presence of T cells in the tumors positively correlated with the development of tumor-specific immune responses."

An important finding in this study was that no patient had significant tumor specific immune responses before the combined therapy. After the combination treatment, tumor specific responses were observed in 52.9 percent of trial patients.

The researchers reported that the combination treatment was "well tolerated" and that 12 of the 17 patients in the clinical trial were "progression free" after one year.

The authors concluded that given that the combination therapy proved effective in creating a potent anti-tumor response and was safe, producing no adverse side effects, larger trials with greater numbers of patients were warranted.

Provided by H. Lee Moffitt Cancer Center & Research Institute

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Study uses the patient's tumor to form vaccine

Nov 24, 2010

A new process for creating a personalized vaccine may become a crucial tool in helping patients with colorectal cancer develop an immune response against their own tumors. This dendritic cell (DC) vaccine, developed at Dartmouth ...

Gene that suppresses cell's immune activation identified

Mar 24, 2011

(PhysOrg.com) -- A new study of prostate tumors has shown that a gene, FOXO3, suppresses activation of cells related to immunity and thus leads to a reduced immune response against a growing cancer. One of the main ...

Recommended for you

Pepper and halt: Spicy chemical may inhibit gut tumors

1 hour ago

Researchers at the University of California, San Diego School of Medicine report that dietary capsaicin – the active ingredient in chili peppers – produces chronic activation of a receptor on cells lining ...

Expressive writing may help breast cancer survivors

3 hours ago

Writing down fears, emotions and the benefits of a cancer diagnosis may improve health outcomes for Asian-American breast cancer survivors, according to a study conducted by a researcher at the University of Houston (UH).

Taking the guesswork out of cancer therapy

8 hours ago

Researchers and doctors at the Institute of Bioengineering and Nanotechnology (IBN), Singapore General Hospital (SGH) and National Cancer Centre Singapore (NCCS) have co-developed the first molecular test ...

Brain tumour cells found circulating in blood

9 hours ago

(Medical Xpress)—German scientists have discovered rogue brain tumour cells in patient blood samples, challenging the idea that this type of cancer doesn't generally spread beyond the brain.

International charge on new radiation treatment for cancer

10 hours ago

(Medical Xpress)—Imagine a targeted radiation therapy for cancer that could pinpoint and blast away tumors more effectively than traditional methods, with fewer side effects and less damage to surrounding tissues and organs.

User comments